Feb 16, 2021
Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference
Jan 29, 2021
Protagonist Therapeutics Reports Granting of Inducement Award
Jan 04, 2021
Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 16, 2020
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
Dec 10, 2020
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
Dec 10, 2020
Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Dec 07, 2020
Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories
Dec 06, 2020
Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
Dec 02, 2020
Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera
Dec 01, 2020
Protagonist Therapeutics Reports Granting of Inducement Award
Nov 30, 2020
Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020
Nov 25, 2020
Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference
Nov 11, 2020
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference
Nov 04, 2020
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
Oct 30, 2020
Protagonist Therapeutics Reports Granting of Inducement Award
Oct 29, 2020
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen
Oct 21, 2020
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera
Sep 17, 2020
Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020
Sep 15, 2020
Protagonist Therapeutics Reports Granting of Inducement Award
Sep 10, 2020
Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference